Aesthetic medicine once again encounters a concept that seems straight out of a horror film: “zombie filler”. The name, used to refer to certain fillers made from adipose tissue sourced from deceased donors, is as striking as the practice it attempts to describe.
The phenomenon began to attract attention in the United States within a very particular context: the surge of weight-loss treatments based on GLP-1 analogs, such as Ozempic, Wegovy, and Mounjaro. The rapid and pronounced weight loss can also imply a significant reduction in adipose tissue, even in the face, giving rise to what is popularly known as “Ozempic face.”
In that scenario emerged a new aesthetic need: how to recover the lost volume when the body itself no longer has enough fat to perform an autologous transfer.
The topic was recently addressed by Vanitatis, publication that focused on the so-called zombie filler and on the product known as alloClae. From there arises an inevitable question: what exactly are we talking about?
What is a “zombie filler”?
First, a crucial clarification: this is not about extracting fat from a deceased person and injecting it directly into someone else.
The adipose tissue from cadaveric donors undergoes selection, processing, and sterilization. According to the information released about the product, the final material contains intact but non-viable adipocytes, in addition to extracellular matrix, lipids, and connective tissue. In other words, live and functional fat cells from another person are not transplanted.
The aim is to use that processed tissue as a structure that provides volume and can integrate and remodel within the recipient’s body.
And there lies a fundamental difference with the procedure that has been used for years to restore body volume: lipofilling or autologous fat transfer.
“When we talk about using fat to increase body volume, the usual approach is to rely on the patient’s own fat through autologous fat transfer: fat is extracted from one area of the body and used in another,” explains the Dr. Florencia Paniego, dermatologist.
In lipofilling, then, the fat belongs to the patient themselves. It can be extracted, for example, from the abdomen, the flanks, or the thighs and then transferred to another area. A portion of the tissue may reabsorb, while another part can vascularize and integrate as living adipose tissue.
The scenario posed by zombie filler is different: the tissue comes from another person and its cells are not viable.
Why does it appear now?
The popularization of GLP-1 analogue treatments also reshaped the landscape of aesthetic medicine. As more people achieve considerable weight loss, the demand for procedures aimed at recovering certain lost volumes increases.
In the face, that fat loss can become particularly noticeable. Hence the emergence of the term “Ozempic face,” used to describe a sunken or more aged appearance associated with facial volume loss.
But the problem is not limited to the face. It can also involve buttocks, arms, chest, or other areas of the body.
And therein lies one of the questions raised by this new technique: what happens when someone wants to regain volume but does not have enough own adipose tissue?
“I have doubts when procedures are marketed as delivering large volume gains with small amounts of product,” notes the Dr. Cristina Sciales, surgeon and physician, specialist in stress medicine and bioregenerative medicine.
For the specialist, there is a question that should be asked before any procedure: “what exactly is being placed?”
It’s not simply “fat”: it’s a biological tissue
The discussion also forces us to view adipose tissue in a different way.
“Fat tissue is not merely a fat depot: it is a biologically active tissue, with metabolic and endocrine functions. Scientific literature even regards it as an endocrine organ,” explains Paniego.
Therefore, for the dermatologist, if considering using adipose tissue derived from a donor, it should not be thought of as a conventional filler.
“Adipose tissue is located mainly in the subcutaneous tissue or hypodermis, beneath the dermis. Therefore, if one considers using it as donor material, it should be analyzed as a biological tissue and not merely as a filler,” she adds.
The difference is not minor. When a material is introduced into the body, it is not enough to know how much volume it can provide: it also matters what it is, where it comes from, how it was processed, and what happens once it comes into contact with tissues.
“When a material is introduced into the body for cosmetic purposes, it is not enough to evaluate only the desired result. One must know what it is, where it comes from, how it was processed, what it was developed for, and what evidence exists regarding its safety,” argues Sciales.
Does the body reject tissue from another person?
One of the questions that can provoke the most concern when discussing donor tissue is the possibility of rejection.
The explanation is that the processed material does not contain living, functional adipose cells from the donor. The proposal is that the matrix and the structural tissue serve as support and, subsequently, integrate and remodel with the recipient’s tissues.
The results released so far include preclinical observations and studies in animal models, where vascularization and the appearance of new host adipocytes have been noted. However, one of the main unanswered questions is what happens over the years in human beings.
And that point is central for Paniego.
“In medicine it is important to distinguish between what can be raised as a possibility, what is being researched, and what is actually authorized and used in clinical practice. Not everything done or promoted in other countries can be automatically translated into our reality,” she warns.
What risks does it carry?
As with any procedure that involves introducing a material into the body, there are potential complications.
Among the adverse effects described for these materials are pain, hematomas, infection, pigment changes, cyst or nodule formation, and various immune responses. There is also a residual risk of transmission of donor-associated diseases, although the processes of selection, control, and sterilization aim to reduce it.
But the most important question is not necessarily what is already known, but what remains not sufficiently understood.
The lack of prolonged clinical follow-up is one of the concerns raised by the specialists interviewed.
“Before presenting a new technique as an aesthetic innovation, one must know very well what is being placed,” maintains Sciales.
The specialist also highlights something that often takes a back seat to the before-and-after images: what can happen to the tissue after months or years.
And what if it is used on the buttocks or on the chest?
Body applications raise even more questions.
The FDA states that approved dermal fillers have specific indications and cautions that injectable fillers are not approved to enlarge breasts or buttocks. It also notes that using fillers for large body contouring procedures can lead to serious complications.
Sciales, in that sense, draws a clear distinction between using one’s own fat for certain reconstructive procedures and treating a human-derived material as a conventional aesthetic product.
“In my practice, many years ago I stopped using fat as a filler for cosmetic purposes. I reserved it for very specific reconstructive situations,” she explains.
She adds that, in those cases, she used the patient’s own fat, “knowing that the result could change over time.”
Breast augmentation with these materials also raises another concern: the possible appearance of nodules, cysts, or calcifications could complicate the interpretation of imaging studies such as mammograms and ultrasounds.
Could it be used in Argentina?
For now, the scenario described by the specialists is very different from the United States.
“In Argentina, this type of procedure using donor cadaveric tissue is far from the usual aesthetic practice,” Paniego notes.
The doctor explains that the existence of mechanisms to procure and use human tissues for medical purposes does not mean that any tissue can automatically be used for any purpose.
“That in medicine organs and tissues from cadaveric donors can be used demonstrates that there are mechanisms for procuring, processing, and implanting human tissues. But that does not mean that any tissue can automatically be used for any purpose,” she asserts.
In Argentina, the obtaining and use of human-origin organs, tissues, and cells is covered by a specific legal framework. Therefore, when faced with an eventual aesthetic use of donor cadaveric adipose tissue, questions regarding its procurement, processing, preservation, traceability, indication, evidence of safety and efficacy, and the competent health authorities would need to be addressed.
Sciales also warns that it is not appropriate to automatically transfer the American phenomenon to our country.
“Law 27.447 does not explicitly address ‘zombie fillers’ or ‘cadaveric fat’ used as an aesthetic filler, so it is not appropriate to attribute a prohibition that the statute does not establish,” she clarifies.
The point, then, is not to claim that the procedure is banned in Argentina, but to understand that its potential use would require analysis within what sanitary and legal framework it could be carried out.
The other debate: what does donating tissue for cosmetic use mean?
There is, moreover, a dimension that goes beyond the strictly medical.
For decades, medicine has used donor tissues for various purposes: corneas, bones, tendons, skin, and other tissues can be part of medical and reconstructive treatments.
But using human tissue for purely cosmetic purposes raises another question: what was consented in donation and what will be its final destination?
Paniego believes there is a legitimate debate there.
“It is not the same to donate tissue to treat a disease or reconstruct a consequence as to use it for purely cosmetic purposes, and I think it is reasonable that there be a social and bioethical discussion about this.”
The question does not have a simple answer, and it is not necessary to have one to analyze the phenomenon. The emergence of these new materials obliges a discussion about what place human tissues occupy in aesthetic medicine and what the limits should be.
The speed of networks versus the speed of medicine
For Sciales, the phenomenon also brings to light the role of social media.
“There are influencers who show body transformations as if certain procedures were simple, quick, and almost without consequences,” she notes.
The doctor believes that in a post, fundamental information often does not appear: what product was used, how much, who performed the procedure, in what conditions, or what may happen over time.
“When a person with substantial exposure presents a procedure as aspirational, it can become a trend long before there is a real discussion about its risks,” she adds.
And she summarizes her stance with a line that almost serves as a rule for any cosmetic procedure: “Aesthetic medicine cannot keep pace with social media. A procedure does not become safe just because it becomes a trend.”
Therefore, in the face of a technique that combines weight loss, new aesthetic demands, and a material as controversial as donor cadaveric adipose tissue, the questions appear as important as the answers.
“Before accepting any treatment, there are questions that should be non-negotiable: what they will place me with, what its composition is, where it comes from, whether it is authorized for that use, who will apply it, and what complications could arise,” concludes Sciales.
And Paniego raises one last distinction that helps place the phenomenon in context: that a practice exists in another country does not mean it can be automatically transferred to the Argentine reality.
The so-called “zombie filler” may mark the next frontier of aesthetic medicine or remain an experimental trend of a specific moment. For now, one of the most relevant questions seems to be precisely this: separating what is innovative from what has been proven and separating what is promoted from what safety and efficacy have already been sufficiently demonstrated.
Acknowledgments:
Dr. Florencia Paniego – Dermatologist, MN94.996 IG @draflorenciapaniego
Dr. Cristina Sciales, surgeon-physician, specialist in stress medicine and bioregenerative MN 66.744 @csciales
Nara Briega @remota.pr
